I'm not sure if anyone posted this previously (I've been paying less attention to this forum recently... war in Ukraine is more interesting to me right now than the COVID-related policies of a resort I'm not planning to visit in the near future), but here's some interesting data on the BA-2 subvariant of omicron. It now constitutes about 55% of all US cases. The good news is that at least for now, this new variant doesn't seem to causing any increase in numbers. Total cases are down 9%, hospitalizations are down 34%, ICU cases by 41% and deaths by 42%. That would imply to me that BA-2 is no more infectious or serious than B.1.1.529, and there likely is very good cross-immunity between the two sub-strains.
The bad news is that sotrovimab infusions don't seem to work against BA-2, but oral paxlovid still shows really good efficacy. Now that our supplies of the latter medication are more robust, this should be the preferred treatment. Pairing this with the flood of home tests, we can now much more easily diagnose and treat COVID within the therapeutic window for the medications.
So, looks like we probably won't see a BA-2 driven spike in cases, hospitalizations or deaths.